Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023486 · ClinicalTrials.gov registry record · Phase 1
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, sponsored by Novita Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 18
- Study locations
NCT05023486 is a Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies that is actively recruiting participants, run by Novita Pharmaceuticals. The registered enrollment target is 140 participants. The trial reports 18 study locations across 13 states.
The verdict
NCT05023486, a Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, is actively recruiting participants, sponsored by Novita Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 18
- Study locations
Study Summary
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Conditions Studied
Interventions
- DRUG NP-G2-044 Monotherapy
- DRUG Anti-PD-1 Therapy
- DRUG NP-G2-044 Combination therapy
Study Locations (18)
California
- City of Hope - Duarte
- City of Hope Irvine Lennar - Irvine
- Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates - Newport Beach
Arizona
- Honor Health Research Institute - Scottsdale
- University of Arizona - Cancer Center - Tucson
Ohio
- University of Cincinnati (UC) - Cancer Institute - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Virginia
- Virginia Cancer Specialists - Fairfax
- Virginia Commonwealth University - Massey Cancer Center - Richmond
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Nuvance Health - Norwalk
Florida
- University of Florida (UF) - Shands Cancer Center - Gainesville
Indiana
- Indiana University (IU) Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023486
The ClinicalTrials.gov registry entry for NCT05023486 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novita Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Solid Tumor Malignancies appearing as the primary indexed condition, and to 3 interventions - of which NP-G2-044 Monotherapy is the first listed.
NCT05023486 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Arizona, Ohio.
Frequently Asked Questions
What is clinical trial NCT05023486 about?
NCT05023486 is a clinical study titled "NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies". Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
What is the current status of trial NCT05023486?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-12-07. Estimated completion is 2026-09-30.
What conditions does trial NCT05023486 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumor Malignancies.
What interventions are being tested in trial NCT05023486?
The interventions under investigation include: NP-G2-044 Monotherapy (DRUG), Anti-PD-1 Therapy (DRUG), NP-G2-044 Combination therapy (DRUG).
Who is sponsoring clinical trial NCT05023486?
This trial is sponsored by Novita Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023486 being conducted?
This trial has 18 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.